​

Larimar Therapeutics Stock (NASDAQ:LRMR)

ForecastRevenueOwnershipFinancialsChart
Larimar Therapeutics by TradingView

Previous Close

$3.88

52W Range

$1.61 - $9.50

50D Avg

$2.82

200D Avg

$3.94

Market Cap

$233.06M

Avg Vol (3M)

$1.26M

Beta

0.86

Div Yield

-

LRMR Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

65

IPO Date

Jun 19, 2014

Website

LRMR Performance

LRMR Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-90.89M$-41.76M$-36.53M
Net Income$-80.60M$-36.95M$-34.18M
EBITDA$-90.89M$-41.45M$-35.08M
Basic EPS$-1.32$-0.84$-1.33
Diluted EPS$-1.32$-0.84$-1.33

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
GOSSGossamer Bio, Inc.
LYRALyra Therapeutics, Inc.
KROSKeros Therapeutics, Inc.
TARAProtara Therapeutics, Inc.
OLMAOlema Pharmaceuticals, Inc.
ORICORIC Pharmaceuticals, Inc.
REPLReplimune Group, Inc.
INZYInozyme Pharma, Inc.
NVCTNuvectis Pharma, Inc.